20/20 GeneSystems was founded to develop and promote an innovative proteomics product line that provides drug companies, biodefense specialists and life scientists with new tools for protein analysis. The company’s first product, and the focus of the company’s work through MIPS, called BioCheck®, is the “gold standard” test for the screening of unknown suspicious powders by emergency personnel and first responders.  Since developing BioCheck, the company has expanded its scope to developing and commercializing innovative, proprietary diagnostic tests that aid in the fight against cancer. These tests generally fall into three categories: personalized medicine, early detection of lung cancer, and biological detection.